DURECT Corporation, a biopharmaceutical company, researches and develops medicines based on its epigenetic regulator and pharmaceutical programs. The company offers ALZET product line that consists of osmotic pumps and accessories used for experimental research in mice, rats, and other laboratory animals; and a range of biodegradable polymers for pharmaceutical and medical device clients for use as raw materials in their products under the LACTEL brand.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone408-777-1417
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$18.56 million
Profitability
Miscellaneous
Employees88
Next Earnings Date11/6/2019 (Estimated)
OptionableOptionable
DURECT (NASDAQ:DRRX) Frequently Asked Questions
What is DURECT's stock symbol?
DURECT trades on the NASDAQ under the ticker symbol "DRRX."
How were DURECT's earnings last quarter?
DURECT Co. (NASDAQ:DRRX) posted its earnings results on Thursday, August, 1st. The specialty pharmaceutical company reported ($0.04) earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($0.05) by $0.01. The specialty pharmaceutical company earned $3.99 million during the quarter, compared to analysts' expectations of $4.05 million. DURECT had a negative net margin of 123.22% and a negative return on equity of 116.97%. View DURECT's Earnings History.
When is DURECT's next earnings date?
What price target have analysts set for DRRX?
3 brokers have issued 12 month price targets for DURECT's stock. Their predictions range from $2.10 to $5.00. On average, they expect DURECT's stock price to reach $3.53 in the next year. This suggests a possible upside of 77.6% from the stock's current price. View Analyst Price Targets for DURECT.
What is the consensus analysts' recommendation for DURECT?
3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for DURECT in the last year. There are currently 1 hold rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for DURECT.
Has DURECT been receiving favorable news coverage?
Press coverage about DRRX stock has trended somewhat negative this week, according to InfoTrie Sentiment. The research firm identifies positive and negative news coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. DURECT earned a news impact score of -1.5 on InfoTrie's scale. They also assigned news coverage about the specialty pharmaceutical company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the company's share price in the immediate future. View News Stories for DURECT.
Are investors shorting DURECT?
DURECT saw a increase in short interest during the month of September. As of September 30th, there was short interest totalling 1,370,000 shares, an increase of 79.3% from the August 30th total of 763,900 shares. Based on an average daily volume of 1,160,000 shares, the days-to-cover ratio is presently 1.2 days. Approximately 1.0% of the company's shares are sold short. View DURECT's Current Options Chain.
Who are some of DURECT's key competitors?
Some companies that are related to DURECT include Heron Therapeutics (HRTX), Nabriva Therapeutics (NBRV), Ironwood Pharmaceuticals (IRWD), Madrigal Pharmaceuticals (MDGL), Supernus Pharmaceuticals (SUPN), Eidos Therapeutics (EIDX), Opko Health (OPK), Radius Health (RDUS), BELLUS Health (BLUSF), Enanta Pharmaceuticals (ENTA), Zymeworks (ZYME), Turning Point Therapeutics (TPTX), ArQule (ARQL), Innoviva (INVA) and Endo International (ENDP).
What other stocks do shareholders of DURECT own?
Who are DURECT's key executives?
DURECT's management team includes the folowing people:
- Dr. James E. Brown, Co-Founder, CEO, Pres & Director (Age 62)
- Mr. Matthew J. Hogan, CFO & Sec. (Age 59)
- Ms. Judy R. Joice, Sr. VP of Operations & Corp. Quality Assurance (Age 62)
- Mr. Michael H. Arenberg, Chief Financial Officer (Age 49)
- Dr. John W. Gibson B.S., M.S., VP of Birmingham Operations & Principal Scientist
Who are DURECT's major shareholders?
DURECT's stock is owned by a number of of retail and institutional investors. Top institutional investors include Ingalls & Snyder LLC (4.27%) and Assenagon Asset Management S.A. (0.23%). Company insiders that own DURECT stock include First Eagle Investment Managem, James E Brown, Jon S Saxe and Michael Arenberg. View Institutional Ownership Trends for DURECT.
Which institutional investors are selling DURECT stock?
Which institutional investors are buying DURECT stock?
DRRX stock was acquired by a variety of institutional investors in the last quarter, including Assenagon Asset Management S.A.. Company insiders that have bought DURECT stock in the last two years include First Eagle Investment Managem, James E Brown, Jon S Saxe and Michael Arenberg. View Insider Buying and Selling for DURECT.
How do I buy shares of DURECT?
Shares of DRRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is DURECT's stock price today?
One share of DRRX stock can currently be purchased for approximately $1.99.
How big of a company is DURECT?
DURECT has a market capitalization of $381.96 million and generates $18.56 million in revenue each year. The specialty pharmaceutical company earns $-25,320,000.00 in net income (profit) each year or ($0.16) on an earnings per share basis. DURECT employs 88 workers across the globe.View Additional Information About DURECT.
What is DURECT's official website?
How can I contact DURECT?
DURECT's mailing address is 10260 BUBB RD, CUPERTINO CA, 95014. The specialty pharmaceutical company can be reached via phone at 408-777-1417.
MarketBeat Community Rating for DURECT (NASDAQ DRRX)
MarketBeat's community ratings are surveys of what our community members think about DURECT and other stocks. Vote "Outperform" if you believe DRRX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe DRRX will underperform the S&P 500 over the long term. You may vote once every thirty days.
